Physician profile
Sarpreet Bindra
NPI 1740541820
$1,196.53
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $133 · 2021: $150 · 2022: $161 · 2023: $279 · 2024: $232 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.19 | 2020-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $158.28 | 2023-2025 | Freestyle Libre 2 |
| Novo Nordisk INC | $156.75 | 2019-2025 | Wegovy |
| Pfizer INC. | $140.10 | 2019-2024 | |
| Astellas Pharma US INC | $87.83 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $40.50 | 2019-2024 | Trelegy Ellipta |
| Sunovion Pharmaceuticals INC. | $22.82 | 2022 | |
| Dexcom, INC. | $22.62 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.89 | 2022 | |
| Amarin Pharma, INC. | $17.89 | 2020 | |
| Amgen INC. | $17.00 | 2019 | |
| Sumitomo Pharma America, INC. | $16.04 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $14.39 | 2024 | |
| Lilly USA, LLC | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarpreet Bindra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.